Thursday, October 10, 2019 Daily Archives

Glenmark taps CHO cell line from Horizon Discovery

by

Glenmark Pharmaceuticals says it has integrated Horizon’s GS knockout CHO K1 platform into its cell line portfolio and will use it to develop future monoclonal antibodies. After what Glenmark Pharmaceuticals said was a “stringent evaluation of the cell line,†the drugmaker has licensed Horizon Dscovery’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line. According to a Glenmark spokesperson, Horizon’s CHO-based cell line demonstrated consistently impressive performance, with high levels of productivity, favorable stability profile, and transparent…

October 10, 2019

Novo Nordisk and bluebird to develop ‘once and done’ hemophilia gene therapy

by

The three-year collaboration will use bluebird bio’s mRNA-based megaTAL gene editing technology to develop a one-off therapy for patients with hemophilia. Novo Nordisk has had a longstanding focus on the hemophilia space. The Danish drugmaker has marketed several replacement factors for hemophilia patients and has a monoclonal antibody in Phase II studies: Concizumab, a Tissue Factor Pathway Inhibitor (TFPI) intended for bleeding prevention after subcutaneous administration. But a partnership announced this week with regenerative medicine firm bluebird bio will look…

October 10, 2019